aspirin + atorvastatin + perindopril

This is a **fixed-dose combination** of three agents: **aspirin**, **atorvastatin**, and **perindopril**. - **Aspirin** is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 synthesis, thereby inhibiting platelet aggregation and providing cardiovascular protection. - **Atorvastatin** is a statin that inhibits HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver, leading to decreased LDL cholesterol and overall lipid lowering. - **Perindopril** is an angiotensin-converting enzyme (ACE) inhibitor, a prodrug metabolized to perindoprilat, which blocks the conversion of angiotensin I to angiotensin II, resulting in vasodilation, reduced blood pressure, and cardiovascular protection. The combination aims to provide comprehensive secondary prevention for patients with established or high-risk cardiovascular disease, targeting platelet aggregation, lipid levels, and blood pressure simultaneously. Fixed-dose triple therapy may improve adherence and convenience compared to taking three separate drugs. This combination is being explored for both **primary and secondary prevention** of atherosclerotic cardiovascular disease, such as in patients with a history of myocardial infarction or those at high risk due to hypertension, hypercholesterolemia, or other risk factors[5].

Other names

aspirin + atorvastatin + perindopril combination therapyONCE trial combination